Alexza Pharmaceuticals, Inc.
http://www.alexza.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alexza Pharmaceuticals, Inc.
Teva And mAbxience Join Forces On Unnamed Oncology Biosimilar
Teva continues to find comfort with an ally on biosimilar development, striking a deal with the Fresenius-Kabi-backed mAbxience for an undisclosed oncology biosimilar.
JPM 2024: ‘Economic Engine:’ Genomics News Abound From Exact, Guardant And Veracyte
The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.
Intas And mAbxience Strike Global Etanercept Deal
Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.
Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
Company Information
- Other Names / Subsidiaries
-
- Addicere Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice